618 completed, 201 unknown, 185 terminated, 151 recruiting. 611 Phase 2, 504 Phase 1, 100 Not applicable, 91 Phase 3, 29 Phase 4.
Follow Lymphoma, T-Cell: new trials by email Literature Review of Lymphoma, T-Cell trials Research Report on Lymphoma, T-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FLASH Pilot Phase 1 Safety Study IntraOp Mobetron UHDR, Linac - Cutaneous Lymphoma | Not applicable | Not yet recruiting | Lesley A. Jarvis | 10 | 2029-10-31 | 2026-05-27 |
| Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma Sugemalimab, Placebo, Pegaspargase - Extranodal NK/T-cell Lymphoma | Phase 3 | Not yet recruiting | CStone Pharmaceuticals | 150 | 2027-06-01 | 2026-05-27 |
| Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) Autologous C7R.CD30-CAR-EBVSTs - Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma | Phase 1 | Not yet recruiting | The Methodist Hospital Research Institute | 21 | 2027-01-15 | 2026-07-27 |
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-10-30 |
| Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution APR-TD011 (RLF-TD011) - Cutaneous T Cell Lymphoma | Early Phase 1 | Not yet recruiting | Northwestern University | 30 | 2027-01-01 | 2026-05-01 |
| A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides Duvelisib - Mycosis Fungoides, Cutaneous T-cell Lymphoma | Phase 1 | Not yet recruiting | SecuraBio | 30 | 2027-01-01 | 2026-07-20 |
| Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia Golidocitinib - Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Washington University School of Medicine | 24 | 2026-12-31 | 2026-11-05 |
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
| A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma Stapokibart, immune checkpoint inhibitor - Lymphoma, NK T-Cell Lymphoma | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 20 | 2026-12-01 | 2026-08-28 |
| Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38. GNTbm-38 - Solid Tumor (Phase I), Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Phase 1 | Not yet recruiting | Great Novel Therapeutics Biotech & Medicals Corporation | 70 | 2026-12-01 | 2026-09-25 |
| BV-CHP Real-life and Biological Evidences in Patients With sALCL Anaplastic Large Cell Lymphoma | Not yet recruiting | Fondazione Italiana Linfomi - ETS | 100 | 2026-11-01 | 2026-10-26 | |
| A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Medsyn Biopharma, LLC | 75 | 2026-11-01 | 2026-10-27 |
| Allogeneic Cell Therapy in Refractory T-Cell Lymphoma Baseline FDG-PET/CT, First-line chemotherapy, Interim FDG-PET/CT after two cycles of first-line chemotherapy - Lymphoma, T Cell, Peripheral | Phase 2 | Not yet recruiting | University Medical Center Goettingen | 70 | 2026-11-01 | 2026-11-05 |
| A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma Zeprumetostat Tablets - Cutaneous T-Cell Lymphoma/Mycosis Fungoides/Sézary Syndrome | Phase 2 | Not yet recruiting | Peking University First Hospital | 33 | 2026-10-31 | 2026-10-02 |
| A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma KK2223 - T-cell NHL (PTCL or CTCL) | Phase 1 | Recruiting | Kyowa Kirin, Inc. | 72 | 2026-09-02 | 2026-09-30 |
| Topical JAK-Inhibition of Early-Stage CTCL delgocitinib - Mycosis Fungoides, Cutaneous T-cell Lymphoma | Phase 2 | Not yet recruiting | Aarhus University Hospital | 15 | 2026-09-01 | 2026-08-26 |
| GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma Gemcitabine (GEM), Etoposide Injection, Dexamethasone - Natural Killer/T-cell Lymphoma | Phase 2 | Not yet recruiting | Fudan University | 620 | 2026-09-01 | 2026-08-17 |
| A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies HY035 cell injection - Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory | Phase 1 | Enrolling by invitation | Institute of Hematology & Blood Diseases Hospital, China | 13 | 2026-08-15 | 2026-08-25 |
| Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases Extranodal NK/T-cell Lymphoma, Aggressive NK-Cell Leukemia | Recruiting | Rong Tao | 1500 | 2026-08-11 | 2026-08-13 | |
| BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL GELAD regimen, MEDA regimen, LEAP regimen - Extranodal NK/T-cell Lymphoma | Phase 3 | Recruiting | Rong Tao | 150 | 2026-08-11 | 2026-08-13 |
Showing 20 of 1347. Sign in to see all of them.
Lymphoma, T-Cell, Cutaneous (551) · Mycosis Fungoides (445) · Lymphoma, Large B-Cell, Diffuse (424) · Lymphoma (415) · Lymphoma, Non-Hodgkin (411) · Lymphoma, Large-Cell, Anaplastic (394) · Lymphoma, Follicular (373) · Hodgkin Disease (370) · Sezary Syndrome (366) · Lymphoma, Mantle-Cell (363) · Leukemia, Lymphocytic, Chronic, B-Cell (362) · Lymphoma, T-Cell, Peripheral (362) · Lymphoma, B-Cell, Marginal Zone (345) · Burkitt Lymphoma (343) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (341)
Neoplasms by Histologic Type (1341) · Neoplasms (1278) · Hemic and Lymphatic Diseases (1266) · Lymphatic Diseases (1259) · Immunoproliferative Disorders (1256) · Immune System Diseases (1253) · Lymphoproliferative Disorders (1217) · Lymphoma, Non-Hodgkin (936) · Lymphoma (932) · Hematologic Diseases (508) · Pathological Conditions, Signs and Symptoms (475) · Leukemia, Lymphoid (474) · Pathologic Processes (468) · Disease Attributes (456)
Cyclophosphamide (149) · Etoposide (85) · Doxorubicin (69) · Prednisone (69) · Vincristine (66) · Peripheral Blood Stem Cell Transplantation (65) · fludarabine phosphate (64) · Brentuximab Vedotin (59) · Gemcitabine (58) · Methotrexate (50) · Mycophenolic Acid (48) · Whole-Body Irradiation (48) · Rituximab (46) · romidepsin (44) · Busulfan (43)
National Cancer Institute (NCI) (100) · Fred Hutchinson Cancer Center (45) · M.D. Anderson Cancer Center (35) · City of Hope Medical Center (30) · Memorial Sloan Kettering Cancer Center (30) · Ruijin Hospital (28) · Northwestern University (26) · Mayo Clinic (21) · Sun Yat-sen University (20) · Case Comprehensive Cancer Center (16) · European Organisation for Research and Treatment of Cancer - EORTC (16) · Seagen Inc. (16) · Samsung Medical Center (13) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (13) · National Institutes of Health Clinical Center (CC) (12)
United States (794) · China (239) · France (97) · Italy (85) · United Kingdom (73) · Germany (68) · Spain (65) · Canada (60) · South Korea (52) · Australia (46) · Belgium (36) · Japan (32) · Switzerland (29) · Netherlands (27) · Poland (26)
Ajay Gopal (6) · Francine Foss, MD (6) · Rong Tao, MD (6) · Timothy M. Kuzel, MD (6) · Brenda Sandmaier (5) · Madeleine Duvic, MD (5) · Steven Horwitz, MD (5) · Won Seog Kim, MD, PhD (5)
PMID 32632956, PMID 32499241, PMID 34806163, PMID 22510871, PMID 25113753, PMID 33883258, PMID 17242396, PMID 18626005, PMID 20679620, PMID 22045986, PMID 22337718, PMID 22677206, PMID 23069814, PMID 23770157, PMID 24652992, PMID 25135998, PMID 25795722, PMID 28600132, PMID 28911074, PMID 28974506, PMID 31029646, PMID 32508818, PMID 32596842, PMID 32730187, PMID 33051668, PMID 33072126, PMID 34091453, PMID 34702811, PMID 35175355, PMID 35489026, PMID 35536441, PMID 35882475, PMID 39821757, PMID 41774854, PMID 41920422, PMID 10552943, PMID 10764422, PMID 11231324, PMID 11410496, PMID 11675364, PMID 11863096, PMID 11895901, PMID 12097283, PMID 1244564, PMID 12525530, PMID 12543862, PMID 12588222, PMID 12873880, PMID 14585365, PMID 14630682
P30CA015704 (22), P30CA033572 (22), P30CA043703 (12), P30CA015083 (11), P30CA016672 (9), P30CA036727 (9), 2023 (8), P30CA072720 (8), U10CA032102 (8), P30CA068485 (7), P01CA018029 (6), P30CA006973 (6), P30CA022453 (6), P30CA060553 (6), U01CA062502 (6)